Company Focus
CSL Limited.
Latest CSL Limited. News
Biotechnology
Global biotechnology firm CSL Behring has announced that two patients with hemophilia B have been treated with the gene therapy Hemgenix (etranacogene dezaparvovec). 5 July 2024
Related News
Insights
Company Spotlight
A clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies for the treatment of cancer and infectious
diseases
Latest News & Features of interest to CSL Limited.
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Biotechnology
California, USA-based biotech Terray Therapeutics, yesterday announced the closing of an oversubscribed Series B funding of $120 million. 18 October 2024
Pharmaceutical
British artificial intelligence specialist BenevolentAI has announced the return of its founder, Ken Mulvany, as executive chairman. 18 October 2024
Pharmaceutical
The rocky road goes on for Intercept Pharmaceuticals with its primary biliary cholangitis (PBC) candidate Ocaliva (obeticholic acid). 17 October 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has updated the US label for French pharma major Sanofi’s Flublok (Influenza Vaccine) to include data from a new safety study involving pregnant women. 17 October 2024
Biotechnology
The chronic obstructive pulmonary disease (COPD) market in the seven major markets (7MM) is set to grow from $11.5 billion in 2023 to $30.8 billion in 2033, driven by the launch of the first biologic for COPD and other pioneering pipeline agents. 17 October 2024
Biotechnology
Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the news of a setback for its investigational application for a covid vaccine. 17 October 2024
Biotechnology
A new clinical trial sponsored by the National Institutes of Health (NIH) has shown that the Jynneos (MVA-BN) vaccine is safe for adolescents and generates an antibody response similar to that in adults. 17 October 2024
Biotechnology
US RNA medicines biotech Wave Life Sciences yesterday announced positive proof-of-mechanism data from the ongoing Phase Ib/IIa RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD) 17 October 2024
Pharmaceutical
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
Latest In Brief for CSL Limited.
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
30 October 2024
26 October 2024
24 September 2024
19 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze